Literature DB >> 21630030

Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method.

Eleni Aklillu1, Sabina Mugusi, Eliford Ngaimisi, Michael Marcus Hoffmann, Sonja König, Victoria Ziesenitz, Gerd Mikus, Walter Emil Haefeli, Johanna Weiss.   

Abstract

PURPOSE: The 388A>G and the 521T>C polymorphism of the SLCO1B1 gene affect the activity of the uptake transporter OATP1B1, thus influencing kinetics, safety, and efficacy of substrate drugs. To evaluate the impact of these polymorphisms in populations of different ethnic origins, it is important to know their frequencies and to develop fast and reliable methods for genotyping. We therefore established a new, high-throughput method and determined the genotype and allelic frequencies of these polymorphisms in Tanzanians, for which the frequencies were unknown thus far.
METHODS: New LightCycler® 480-based methods with hybridization probes were established and used to genotype 366 Tanzanian and 236 European individuals for 388A>G (rs2306283) and 521T>C (rs4149056) in the SLCO1B1 gene. The methods were validated by direct sequencing of the polymerase chain reaction (PCR) products of heterozygous individuals and checked for intrarun precision repeatability, interrun precision reproducibility, robustness, and deviations from the Hardy-Weinberg equilibrium.
RESULTS: The new methods allow unambiguous identification of the corresponding genotypes. There was a clear difference in allelic distribution between Tanzanians and Europeans, with the 388A>G (rs2306283) being much more prevalent in Tanzanians (87% vs 41%) and the 521T>C (rs4149056) being very rare in this African population (6% vs 17%).
CONCLUSIONS: We developed robust and high-throughput methods to genotype common SLCO1B1 allelic variants with the LightCycler® 480. In Tanzanians, we identified the highest frequency of the 388A>G and 521T>C polymorphisms ever reported from black populations. The clinical relevance of SLCO1B1 genetic variation in the African population remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21630030     DOI: 10.1007/s00228-011-1065-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  38 in total

1.  Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients.

Authors:  E Ngaimisi; S Mugusi; O M Minzi; P Sasi; K-D Riedel; A Suda; N Ueda; M Janabi; F Mugusi; W E Haefeli; J Burhenne; E Aklillu
Journal:  Clin Pharmacol Ther       Date:  2010-09-29       Impact factor: 6.875

2.  SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.

Authors:  Mikko Niemi; Marja K Pasanen; Pertti J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2006-10       Impact factor: 6.875

3.  Rapid genotyping of the OATP1B1 polymorphisms A388G and T521C with real-time PCR FRET assays.

Authors:  Robert A M Op den Buijsch; Petal A H M Wijnen; Marja P van Dieijen-Visser; Johan E de Vries; Otto Bekers
Journal:  Pharmacogenomics       Date:  2005-06       Impact factor: 2.533

4.  Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients.

Authors:  Xiaoqiang Xiang; Srinivasa Rao Jada; Hui Hua Li; Lu Fan; Lai San Tham; Chiung Ing Wong; Soo Chin Lee; Robert Lim; Qing Yu Zhou; Boon Cher Goh; Eng Huat Tan; Balram Chowbay
Journal:  Pharmacogenet Genomics       Date:  2006-09       Impact factor: 2.089

Review 5.  Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.

Authors:  Mikko Niemi; Marja K Pasanen; Pertti J Neuvonen
Journal:  Pharmacol Rev       Date:  2011-01-18       Impact factor: 25.468

6.  Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.

Authors:  M K Pasanen; H Fredrikson; P J Neuvonen; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2007-05-02       Impact factor: 6.875

7.  Global analysis of genetic variation in SLCO1B1.

Authors:  Marja K Pasanen; Pertti J Neuvonen; Mikko Niemi
Journal:  Pharmacogenomics       Date:  2008-01       Impact factor: 2.533

8.  Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.

Authors:  Alexander Treiber; Ralph Schneiter; Stephanie Häusler; Bruno Stieger
Journal:  Drug Metab Dispos       Date:  2007-05-11       Impact factor: 3.922

9.  SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.

Authors:  I Ieiri; S Suwannakul; K Maeda; H Uchimaru; K Hashimoto; M Kimura; H Fujino; M Hirano; H Kusuhara; S Irie; S Higuchi; Y Sugiyama
Journal:  Clin Pharmacol Ther       Date:  2007-04-25       Impact factor: 6.875

10.  Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1.

Authors:  Stefan Oswald; Jörg König; Dieter Lütjohann; Thomas Giessmann; Heyo K Kroemer; Christian Rimmbach; Dieter Rosskopf; Martin F Fromm; Werner Siegmund
Journal:  Pharmacogenet Genomics       Date:  2008-07       Impact factor: 2.089

View more
  16 in total

1.  A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines.

Authors:  Jorge A Pinto; Edmund V Capparelli; Meredith Warshaw; Bonnie Zimmer; Tim R Cressey; Stephen A Spector; Min Qin; Betsy Smith; George K Siberry; Mark Mirochnick
Journal:  Pediatr Infect Dis J       Date:  2018-02       Impact factor: 2.129

2.  SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia.

Authors:  Paulo Caleb Junior Lima Santos; Ana Carolina Moron Gagliardi; Márcio Hiroshi Miname; Ana Paula Chacra; Raul Dias Santos; Jose Eduardo Krieger; Alexandre Costa Pereira
Journal:  Eur J Clin Pharmacol       Date:  2011-09-18       Impact factor: 2.953

3.  Pharmacokinetics of rosuvastatin in 30 healthy Zimbabwean individuals of African ancestry.

Authors:  Nyarai Soko; Collet Dandara; Raj Ramesar; Gerard Kadzirange; Collen Masimirembwa
Journal:  Br J Clin Pharmacol       Date:  2016-04-13       Impact factor: 4.335

4.  Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1.

Authors:  Christoph Markert; Regina Hellwig; Jürgen Burhenne; Michael Marcus Hoffmann; Johanna Weiss; Gerd Mikus; Walter E Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2013-06-09       Impact factor: 2.953

5.  Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver.

Authors:  Amy Webb; Audrey C Papp; Jonathan C Sanford; Kun Huang; Jeffrey D Parvin; Wolfgang Sadee
Journal:  Pharmacogenet Genomics       Date:  2013-05       Impact factor: 2.089

6.  Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.

Authors:  Christoph Markert; Yvonne Schweizer; Regina Hellwig; Theresia Wirsching; Klaus-Dieter Riedel; Juergen Burhenne; Johanna Weiss; Gerd Mikus; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

7.  SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group.

Authors:  Paulo C J L Santos; Renata A G Soares; Raimundo M Nascimento; George L L Machado-Coelho; José G Mill; José E Krieger; Alexandre C Pereira
Journal:  BMC Med Genet       Date:  2011-10-12       Impact factor: 2.103

8.  Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania.

Authors:  Sabina Mugusi; Eliford Ngaimisi; Mohamed Janabi; Omary Minzi; Muhammad Bakari; Klaus-Dieter Riedel; Juergen Burhenne; Lars Lindquist; Ferdinand Mugusi; Eric Sandstrom; Eleni Aklillu
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

Review 9.  Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.

Authors:  Gurusamy Umamaheswaran; Dhakchinamoorthi Krishna Kumar; Chandrasekaran Adithan
Journal:  Indian J Med Res       Date:  2014-01       Impact factor: 2.375

10.  Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.

Authors:  Eliford Ngaimisi; Abiy Habtewold; Omary Minzi; Eyasu Makonnen; Sabina Mugusi; Wondwossen Amogne; Getnet Yimer; Klaus-Dieter Riedel; Mohammed Janabi; Getachew Aderaye; Ferdinand Mugusi; Leif Bertilsson; Eleni Aklillu; Juergen Burhenne
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.